• Continued development of EmtinB and new asset StemSmart™
• Initiated clinical program for StemSmart™ under TGA Special Access Scheme
• Appointed new CEO and CMO to support key development activities

During the half-year ended December 2025, NeuroScientific Biopharmaceuticals focused on the research and development of its biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. The company undertook several operational activities in support of the development of its lead asset EmtinB and the new asset StemSmart™, which was acquired in June 2025. Upon acquisition of StemSmart™, the company initiated a clinical program, in collaboration with clinicians, utilising the Special Access Scheme (SAS) pathway under the Therapeutic Goods Administration (TGA) to treat patients with fistulising Crohn's disease. The company continued its pre-clinical development of EmtinB as a therapeutic solution for degenerative conditions like glaucoma. The company appointed a new Chief Executive Officer, Nathan Smith, and a new Chief Medical Officer, Dr Catherine Cole, in late July 2025 to support the key development activities that are ongoing. The company also partnered with Q-Gen Cell Therapeutics to initiate the technology transfer of the patented StemSmart™ manufacturing process. Throughout the half-year, the SAS program utilising the StemSmart™ product progressed, with 4 patients identified, approved by the TGA, and treated prior to 31 December 2025. The company continued its pre-clinical development of EmtinB, with a focus on moving towards an intravitreal (IVT) formulation suitable for ocular administration. The loss for the group for the half-year amounted to $1,699,413.